According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “
MRUS has been the subject of a number of other reports. Roth Capital assumed coverage on Merus in a research note on Friday, June 28th. They set a buy rating and a $20.00 price target for the company. BidaskClub downgraded Merus from a buy rating to a hold rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of Buy and a consensus target price of $23.29.
Several institutional investors and hedge funds have recently bought and sold shares of MRUS. Artal Group S.A. raised its stake in shares of Merus by 16.7% during the 2nd quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock worth $5,128,000 after purchasing an additional 50,000 shares in the last quarter. Granite Investment Partners LLC purchased a new stake in shares of Merus during the 1st quarter worth about $468,000. Athanor Capital LP purchased a new stake in shares of Merus during the 2nd quarter worth about $334,000. JPMorgan Chase & Co. raised its stake in shares of Merus by 63.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 3,389 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of Merus by 3.1% in the 2nd quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock valued at $1,359,000 after acquiring an additional 2,788 shares in the last quarter. 52.00% of the stock is owned by institutional investors.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Story: Is it Safe to Invest in Commodities?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.